SIGHT — Gensight Biologics SA Share News
0.000.00%
Last trade - 00:00- €17.21m
- €28.38m
- €0.00m
Brief: Gensight Biologics Receives FDA Fast Track Designation For GS030 Treatment
Brief: GenSight Biologics Announces Publication Of Review Of Gene Therapy Trials For LHON
Brief: Gensight Biologics: positive data safety monitoring board review on PIONEER Phase I/II Clinical Trial of GS030
Brief: Gensight Biologics: update on parameters of ND4-LHON Subjects before LUMEVOQ® treatment in Phase III Trials
GenSight up after gene therapy gets PIM designation in UK
Brief: Gensight' Lumevoq Granted 'Promising Innovative Medicine' Designation
Brief: Gensight's LUMEVOQ, GS030 Data To Be Presented At 2021 ISGEDR
Brief: Gensight Biologics Says Study Data Shows Sustained Efficacy 3 Years After Injection Of Lumevoq
Brief: Gensight Biologics H1 Operating Income Up At EUR 6.9 Million
Brief: Gensight Biologics: France gives LUMEVOQ(®) Cohort Temporary Authorization for Use
Brief: Gensight Biologics Reports Topline Results From Reflect Phase III Clinical Trial
GenSight: Report of visual recovery after optogenetic treatment boosts shares
Brief: Gensight Biologics' GS030 Optogenetic Treatment Shows Promising Results In Nature Report
Brief: GenSight Biologics Says Co Is Financed Until At Least End Of Q2 2023
Brief: Gensight Biologics End-March Cash And Cash Equivalents At EUR 61.1 Mln
Brief: Gensight Biologics Completes A 30 Million Euros Capital Increase
Brief: Gensight Biologics: Capital Increase Of About EUR 25 Million
Brief: Gensight Biologics FY Net Loss Widens To EUR 34.0 Mln
Brief: GenSight Biologics Announces Publication of Results from LUMEVOQ Phase I/IIa Clinical Trial REVEAL